CytomX Therapeutics, Inc. (CTMX) News
Filter CTMX News Items
CTMX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTMX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CTMX News From Around the Web
Below are the latest news stories about CYTOMX THERAPEUTICS INC that investors may wish to consider to help them evaluate CTMX as an investment opportunity.
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 p.m. PT. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. |
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong BuyCytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 - - Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025 - - Revised focus and associated cost and headcount reductions expected to extend cash runway into the second quarter of 2026 - - Company to pre |
KOD Stock Rallies 271% in 6 Months on Eye Disease Program UpdatesKodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases. |
Here's Why Arcutis Stock More Than Doubled in Market Value in One YearThe rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug. |
MESO Stock Surges 80% in a Month After FDA Approval of GVHD DrugMesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older. |
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLACapricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States. |
Neumora Stock Hits Record Low on Depression Drug Study FailureNMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies. |
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product. |
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review TagThe FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%. |